WO2006131013A3 - STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα - Google Patents

STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα Download PDF

Info

Publication number
WO2006131013A3
WO2006131013A3 PCT/CH2006/000300 CH2006000300W WO2006131013A3 WO 2006131013 A3 WO2006131013 A3 WO 2006131013A3 CH 2006000300 W CH2006000300 W CH 2006000300W WO 2006131013 A3 WO2006131013 A3 WO 2006131013A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnfα
antibodies
stable
soluble antibodies
antibodies inhibiting
Prior art date
Application number
PCT/CH2006/000300
Other languages
French (fr)
Other versions
WO2006131013A2 (en
Inventor
Stefan Ewert
Alcide Barberis
David M Urech
Der Maur Adrian Auf
Peter Lichtlen
Original Assignee
Esbatech Ag
Stefan Ewert
Alcide Barberis
David M Urech
Der Maur Adrian Auf
Peter Lichtlen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ563580A priority Critical patent/NZ563580A/en
Priority to BRPI0611765-1A priority patent/BRPI0611765B1/en
Priority to MX2007015280A priority patent/MX2007015280A/en
Priority to KR1020087000199A priority patent/KR101457223B1/en
Priority to AU2006255415A priority patent/AU2006255415B2/en
Priority to KR1020147011105A priority patent/KR101539545B1/en
Priority to CA2609999A priority patent/CA2609999C/en
Priority to US11/916,793 priority patent/US8067547B2/en
Priority to JP2008515021A priority patent/JP5089582B2/en
Priority to EP06741625A priority patent/EP1891110A2/en
Application filed by Esbatech Ag, Stefan Ewert, Alcide Barberis, David M Urech, Der Maur Adrian Auf, Peter Lichtlen filed Critical Esbatech Ag
Priority to CN200680028415.3A priority patent/CN101233154B/en
Priority to MX2015006717A priority patent/MX342638B/en
Publication of WO2006131013A2 publication Critical patent/WO2006131013A2/en
Publication of WO2006131013A3 publication Critical patent/WO2006131013A3/en
Priority to IL187503A priority patent/IL187503A0/en
Priority to US13/245,420 priority patent/US8389693B2/en
Priority to PH12012500758A priority patent/PH12012500758B1/en
Priority to US13/708,500 priority patent/US8691228B2/en
Priority to US14/185,783 priority patent/US9315572B2/en
Priority to IL243270A priority patent/IL243270B/en
Priority to US15/064,067 priority patent/US9683034B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
PCT/CH2006/000300 2005-06-07 2006-06-06 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα WO2006131013A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CN200680028415.3A CN101233154B (en) 2005-06-07 2006-06-06 Suppress the stable of TNF α and soluble antibodies
BRPI0611765-1A BRPI0611765B1 (en) 2005-06-07 2006-06-06 STABLE AND SOLUBLE ANTIBODY OR FRAGMENT THAT SPECIFICALLY BINDS TO TNF-ALFA ITS USES AND DIAGNOSTIC OR THERAPEUTIC COMPOSITION
KR1020087000199A KR101457223B1 (en) 2005-06-07 2006-06-06 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
AU2006255415A AU2006255415B2 (en) 2005-06-07 2006-06-06 Stable and soluble antibodies inhibiting TNFalpha
KR1020147011105A KR101539545B1 (en) 2005-06-07 2006-06-06 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
CA2609999A CA2609999C (en) 2005-06-07 2006-06-06 Stable and soluble antibodies inhibiting tnf.alpha.
US11/916,793 US8067547B2 (en) 2005-06-07 2006-06-06 Stable and soluble antibodies inhibiting TNFα
MX2015006717A MX342638B (en) 2005-06-07 2006-06-06 Stable and soluble antibodies inhibiting tnfî±.
EP06741625A EP1891110A2 (en) 2005-06-07 2006-06-06 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
NZ563580A NZ563580A (en) 2005-06-07 2006-06-06 Stable and soluble antibodies inhibiting TNFaplha
MX2007015280A MX2007015280A (en) 2005-06-07 2006-06-06 Stable and soluble antibodies inhibiting tnf??.
JP2008515021A JP5089582B2 (en) 2005-06-07 2006-06-06 Stable soluble antibody that inhibits TNFα
IL187503A IL187503A0 (en) 2005-06-07 2007-11-20 Stable and soluble antibodies
US13/245,420 US8389693B2 (en) 2005-06-07 2011-09-26 Stable and soluble antibodies inhibiting TNFα
PH12012500758A PH12012500758B1 (en) 2005-06-07 2012-04-18 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
US13/708,500 US8691228B2 (en) 2005-06-07 2012-12-07 Stable and soluble antibodies inhibiting TNFα
US14/185,783 US9315572B2 (en) 2005-06-07 2014-02-20 Stable and soluble antibodies inhibiting TNF alpha
IL243270A IL243270B (en) 2005-06-07 2015-12-21 Stable and soluble antibodies inhibiting tnfα
US15/064,067 US9683034B2 (en) 2005-06-07 2016-03-08 Stable and soluble antibodies inhibiting TNFα

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68797105P 2005-06-07 2005-06-07
US60/687,971 2005-06-07
US78535306P 2006-03-23 2006-03-23
US60/785,353 2006-03-23

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11/916,793 A-371-Of-International US8067547B2 (en) 2005-06-07 2006-06-06 Stable and soluble antibodies inhibiting TNFα
US91679308A A-371-Of-International 2005-06-07 2008-05-27
US13/245,420 Continuation US8389693B2 (en) 2005-06-07 2011-09-26 Stable and soluble antibodies inhibiting TNFα

Publications (2)

Publication Number Publication Date
WO2006131013A2 WO2006131013A2 (en) 2006-12-14
WO2006131013A3 true WO2006131013A3 (en) 2007-01-25

Family

ID=37193351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2006/000300 WO2006131013A2 (en) 2005-06-07 2006-06-06 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα

Country Status (21)

Country Link
US (5) US8067547B2 (en)
EP (3) EP2390267B1 (en)
JP (2) JP5089582B2 (en)
KR (2) KR101457223B1 (en)
CN (2) CN102924597A (en)
AU (1) AU2006255415B2 (en)
BR (1) BRPI0611765B1 (en)
CA (1) CA2609999C (en)
DK (1) DK2390267T3 (en)
ES (1) ES2424042T3 (en)
HK (2) HK1164891A1 (en)
HR (1) HRP20130632T1 (en)
IL (2) IL187503A0 (en)
MX (1) MX2007015280A (en)
NZ (1) NZ563580A (en)
PH (1) PH12012500758B1 (en)
PL (1) PL2390267T3 (en)
PT (1) PT2390267E (en)
RS (1) RS52861B (en)
RU (1) RU2415151C2 (en)
WO (1) WO2006131013A2 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
PL2390267T3 (en) 2005-06-07 2013-09-30 Esbatech A Novartis Co Llc Stable and soluble antibodies inhibiting TNF(alpha)
AU2016200367B2 (en) * 2006-07-10 2017-10-12 Novartis Ag scFv antibodies which pass epithelial and/or endothelial layers
SI2046382T1 (en) * 2006-07-10 2016-12-30 ESBATech an Alcon Biomedical Research Unit LLC scFv ANTIBODIES WHICH PASS EPITHELIAL AND/OR ENDOTHELIAL LAYERS
CN101668771B (en) 2007-03-12 2013-08-21 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Sequence based engineering and optimization of single chain antibodies
KR101540823B1 (en) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 Antibody formulation
PT2164961E (en) 2007-06-25 2015-04-08 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
JP5611820B2 (en) * 2007-06-25 2014-10-22 エスバテック − ア ノバルティスカンパニー エルエルシー Method for modifying antibodies and modified antibodies having improved functional properties
MX2010003114A (en) * 2007-09-25 2010-06-23 Intervet Int Bv Vaccine for the treatment of osteoarthritis.
MX2010005031A (en) 2007-11-12 2010-06-25 U3 Pharma Gmbh Axl antibodies.
US20110189790A1 (en) * 2008-01-21 2011-08-04 Karyn O'neil Methods of Predicting Antibody Solubility
JP2011510667A (en) * 2008-02-05 2011-04-07 デレネックス セラピューティクス アーゲー Antigen-binding polypeptide for cartilage degeneration
ES2771150T3 (en) * 2008-06-25 2020-07-06 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
JP5856480B2 (en) 2008-06-25 2016-02-09 エスバテック − ア ノバルティスカンパニー エルエルシー Humanization of rabbit antibodies using a versatile antibody framework
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
MX2011000006A (en) 2008-06-30 2011-08-03 Esbatech Alcon Biomed Res Unit Functionalized polypeptides.
CN104800147A (en) 2008-07-10 2015-07-29 德勒尼克斯治疗股份公司 Methods and compositions for enhanced delivery of macromolecules
EP2270053A1 (en) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
AU2010247464B2 (en) 2009-05-11 2014-09-11 U3 Pharma Gmbh Humanized AXL antibodies
BR112012025568A2 (en) * 2010-04-07 2017-03-28 Abbvie Inc tnf-? binding proteins.
UY33679A (en) 2010-10-22 2012-03-30 Esbatech STABLE AND SOLUBLE ANTIBODIES
AU2011325990C1 (en) * 2010-11-12 2017-06-08 Nektar Therapeutics Conjugates of an IL-2 moiety and a polymer
AR084210A1 (en) * 2010-12-08 2013-05-02 Abbott Lab PROTEINS OF UNION TO TNF-a
KR102276161B1 (en) 2011-10-25 2021-07-14 프로테나 바이오사이언시즈 리미티드 Antibody formulations and methods
BR112015009892B1 (en) 2012-11-05 2022-12-27 Delenex Therapeutics Ag ANTIBODY AGAINST IL-1 BETA, ITS PRODUCTION METHOD AND USE, ISOLATED NUCLEIC ACID SEQUENCE, VECTOR, COSMETIC, DIAGNOSTIC OR PHARMACEUTICAL COMPOSITION, AND KIT
WO2014096051A1 (en) * 2012-12-21 2014-06-26 Glenmark Pharmaceuticals S.A. Anti her2 antibody formulation
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
CN105263476A (en) 2013-03-13 2016-01-20 库尔制药开发公司 Immune-modifying particles for the treatment of inflammation
CN111138543A (en) * 2013-03-15 2020-05-12 Xencor股份有限公司 Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2015048770A2 (en) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
EP3074039A4 (en) * 2013-11-26 2017-10-11 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
KR20160098277A (en) 2013-12-20 2016-08-18 에프. 호프만-라 로슈 아게 Improved recombinant polypeptide production methods
JP6832707B2 (en) 2014-03-26 2021-02-24 セル メディカ スイッツァランド アーゲー Binding member for TNFα
SG10202008629XA (en) 2014-03-28 2020-10-29 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
ES2607489T3 (en) 2014-05-23 2017-03-31 Ares Trading S.A. Liquid pharmaceutical composition
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
PL2946765T3 (en) 2014-05-23 2017-08-31 Ares Trading S.A. Liquid pharmaceutical composition
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EA037065B1 (en) 2014-11-26 2021-02-01 Ксенкор, Инк. Heterodimeric antibodies that bind cd3 and cd38
LT3223845T (en) 2014-11-26 2021-08-25 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
HRP20220304T1 (en) 2015-06-24 2022-05-13 F. Hoffmann - La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
ES2716900T3 (en) * 2015-11-06 2019-06-17 Promise Advanced Proteomics A method to quantify anti-TNF antibodies
EP3165922B1 (en) 2015-11-06 2020-06-17 Promise Proteomics A method for quantifying therapeutic antibodies
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
CN109563161A (en) 2016-02-03 2019-04-02 安口生物公司 For improving the buffer preparation of Antibody stability
MA43716A (en) 2016-03-17 2018-11-28 Numab Innovation Ag ANTI-TNF ANTIBODIES AND FUNCTIONAL FRAGMENTS OF THEM
CN109153718B (en) 2016-03-17 2022-02-08 努玛治疗有限公司 anti-TNF alpha antibodies and functional fragments thereof
DK3219727T3 (en) 2016-03-17 2021-01-04 Tillotts Pharma Ag Anti-THF alpha antibodies and functional fragments thereof
ES2836349T3 (en) 2016-03-17 2021-06-24 Tillotts Pharma Ag Anti-TNF-alpha antibodies and functional fragments thereof
JP7049311B2 (en) 2016-03-17 2022-04-06 ヌマブ イノヴェイション アーゲー Anti-TNFα antibodies and their functional fragments
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CA3046019A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
JP2020513280A (en) 2016-12-14 2020-05-14 プロジェニティ， インコーポレイテッド Treatment of digestive tract diseases with immunosuppressants
CN110072551B (en) 2016-12-14 2023-05-23 比奥拉治疗股份有限公司 Treatment of gastrointestinal disorders using IL-12/IL-23 inhibitors released using ingestible devices
KR20190097107A (en) 2016-12-14 2019-08-20 프로제너티, 인크. Treatment and apparatus of gastrointestinal diseases with JAK inhibitors
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
ES2938609T3 (en) 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparation of Solid Dosage Forms Comprising Antibodies by Solution/Suspension Layering
ES2938608T3 (en) 2017-09-20 2023-04-13 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
WO2019226829A1 (en) 2018-05-22 2019-11-28 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US20220025021A1 (en) * 2018-11-21 2022-01-27 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
EP3917954A1 (en) 2019-01-31 2021-12-08 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
PE20212185A1 (en) 2019-02-18 2021-11-11 Lilly Co Eli FORMULATION OF THERAPEUTIC ANTIBODIES
KR20210134725A (en) 2019-03-01 2021-11-10 젠코어 인코포레이티드 Heterodimeric Antibodies that Bind to ENPP3 and CD3
CN111909267B (en) * 2019-05-07 2022-03-25 北京天成新脉生物技术有限公司 Low-immunogenicity anti-TNF-alpha humanized monoclonal antibody TCX063 and its application
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc Anti-cd28 compositions
KR20230156079A (en) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Heterodimeric antibody binding to CD3 and CLDN6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011383A1 (en) * 1990-12-21 1992-07-09 Celltech Limited RECOMBINANT ANTIBODIES SPECIFIC FOR TNF$g(a)
WO2003097697A2 (en) * 2002-05-22 2003-11-27 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2000318A (en) 1933-05-22 1935-05-07 James H Cannon Cord connecter
US2200203A (en) 1938-12-16 1940-05-07 William W Heintz Legend sheet and method of application
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5644034A (en) * 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DE69233254T2 (en) * 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
US5198030A (en) 1991-06-18 1993-03-30 E. I. Du Pont De Nemours And Company Bead edge guide for use in slide-bead coating
ATE204299T1 (en) * 1993-03-05 2001-09-15 Bayer Ag HUMAN MONOCLONAL ANTI-TNF ALPHA ANTIBODIES
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
TR199801532T2 (en) 1996-02-09 1998-11-23 Basf Aktiengesellschaft Human antibodies that bind human TNFalpha.
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2190087T3 (en) * 1997-06-13 2003-07-16 Genentech Inc STABILIZED FORMULATION OF AN ANTIBODY.
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US20030185826A1 (en) 1999-02-24 2003-10-02 Tobinick Edward L. Cytokine antagonists for the treatment of localized disorders
DE60012980T2 (en) 1999-12-28 2005-08-18 Esbatech Ag INTRAKÖRPER WITH DEFINED STRUCTURE ("FRAMEWORK") STABLE IN A REDUCING ENVIRONMENT AND ITS USES
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6406863B1 (en) * 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
SG97908A1 (en) * 2000-08-03 2003-08-20 Inst Data Storage A method and apparatus for load/unload testing of disk drives
US6881407B2 (en) 2000-08-11 2005-04-19 Ashok Amin Method for treating hepatitis
WO2003047510A2 (en) 2001-11-30 2003-06-12 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
PL2390267T3 (en) * 2005-06-07 2013-09-30 Esbatech A Novartis Co Llc Stable and soluble antibodies inhibiting TNF(alpha)
ZA200710109B (en) * 2005-06-07 2009-10-28 Esbatech Ag Stable and soluble antibodies inhibiting TNFALPHA
PT2164961E (en) * 2007-06-25 2015-04-08 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011383A1 (en) * 1990-12-21 1992-07-09 Celltech Limited RECOMBINANT ANTIBODIES SPECIFIC FOR TNF$g(a)
WO2003097697A2 (en) * 2002-05-22 2003-11-27 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AUF DER MAUR A ET AL: "Antigen-independent selection of intracellular stable antibody frameworks", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 34, no. 2, October 2004 (2004-10-01), pages 215 - 224, XP004526807, ISSN: 1046-2023 *
DORING E ET AL: "IDENTIFICATION AND CHARACTERIZATION OF A TNFALPHA ANTAGONIST DERIVED FROM A MONOCLONAL ANTIBODY", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 31, no. 14, 1994, pages 1059 - 1067, XP000872745, ISSN: 0161-5890 *
EWERT S ET AL: "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 34, no. 2, October 2004 (2004-10-01), pages 184 - 199, XP004526805, ISSN: 1046-2023 *

Also Published As

Publication number Publication date
PH12012500758A1 (en) 2016-01-11
ES2424042T3 (en) 2013-09-26
EP1891110A2 (en) 2008-02-27
KR20140071450A (en) 2014-06-11
HRP20130632T1 (en) 2013-11-22
RU2415151C2 (en) 2011-03-27
KR101457223B1 (en) 2014-11-04
US20090263382A1 (en) 2009-10-22
IL187503A0 (en) 2008-03-20
JP2013027390A (en) 2013-02-07
HK1164891A1 (en) 2012-09-28
KR101539545B1 (en) 2015-07-24
BRPI0611765A2 (en) 2011-12-20
NZ563580A (en) 2010-09-30
JP2008545433A (en) 2008-12-18
PT2390267E (en) 2013-07-16
US20160185850A1 (en) 2016-06-30
EP2390267B1 (en) 2013-06-05
US8389693B2 (en) 2013-03-05
EP2390267A1 (en) 2011-11-30
DK2390267T3 (en) 2013-08-26
PL2390267T3 (en) 2013-09-30
BRPI0611765B1 (en) 2022-09-27
IL243270A0 (en) 2016-02-29
US9315572B2 (en) 2016-04-19
WO2006131013A2 (en) 2006-12-14
AU2006255415A1 (en) 2006-12-14
JP5089582B2 (en) 2012-12-05
PH12012500758B1 (en) 2016-01-11
US20120064077A1 (en) 2012-03-15
CN105153306B (en) 2020-12-11
US20140171634A1 (en) 2014-06-19
CN102924597A (en) 2013-02-13
US20130171143A1 (en) 2013-07-04
US8067547B2 (en) 2011-11-29
EP3260465A1 (en) 2017-12-27
IL243270B (en) 2020-09-30
KR20080031003A (en) 2008-04-07
HK1218653A1 (en) 2017-03-03
US9683034B2 (en) 2017-06-20
RS52861B (en) 2013-12-31
MX2007015280A (en) 2008-04-08
AU2006255415B2 (en) 2011-10-06
RU2007149255A (en) 2009-07-20
CN105153306A (en) 2015-12-16
CA2609999C (en) 2017-05-30
CA2609999A1 (en) 2006-12-14
JP5645890B2 (en) 2014-12-24
US8691228B2 (en) 2014-04-08

Similar Documents

Publication Publication Date Title
WO2006131013A3 (en) STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
WO2009155723A3 (en) STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
MX351499B (en) STABLE and SOLUBLE ANTIBODIES.
WO2011020783A3 (en) Targeted immunoconjugates
WO2010033279A3 (en) Antibodies with altered binding to fcrn and methods of using same
TW200740844A (en) Novel MAdCAM antibodies
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2006068975A3 (en) Binding proteins specific for human matriptase
WO2006113277A3 (en) Multivalent soluble tyrokinase receptor that bind angiogenic factor
WO2007031222A3 (en) Identification of tumor-associated antigens for diagnosis and therapy
WO2007035771A3 (en) Modulation of glucagon receptor expression
WO2010021697A3 (en) Antibodies to ccr2
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2006076678A3 (en) Prostate stem cell antigen vaccines and uses thereof
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2006028936A3 (en) Heteromultimeric molecules
WO2009062195A3 (en) Fusion proteins of mannose binding lectins for treatment of disease
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2004081028A3 (en) Allergen peptide fragments and use thereof
WO2006029176A3 (en) Cancer-testis antigens
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
WO2008067408A3 (en) Method of isolating and propagating stem cells from benign tumors
WO2004046332A3 (en) Amplified genes involved in cancer
WO2006047728A3 (en) Bmp gene and fusion protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 187503

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 563580

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12007502664

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2609999

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2006741625

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006741625

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/015280

Country of ref document: MX

Ref document number: 2006255415

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008515021

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 9603/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006255415

Country of ref document: AU

Date of ref document: 20060606

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006255415

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087000199

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007149255

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200680028415.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006741625

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11916793

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0611765

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071207

WWE Wipo information: entry into national phase

Ref document number: 242304

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 243270

Country of ref document: IL